Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

DocRosen Nov. 15 at 3:30 AM

$NSPR ok quit with the rally. I’m trying to buy more.

0 · Reply

LiquidThetaOptions Nov. 15 at 1:04 AM

💎 LiquidTheta® Live Actionable Trade Asset: $NSPR Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $0.41- $0.51 Scale out: $1.61-$2.76 Profit Potential : 77% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Threeways Nov. 14 at 9:14 PM

$NSPR wheres all the complainers at 3 days of gaining off what it lost and its silence. Cant even say anything positive ever

1 · Reply

HedgeAlerts Nov. 14 at 6:30 PM

Hedge Alert Live - Protect Your Portfolio Contract: $NSPR $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.80 - $3.20 Exit Price Target: $1.29 Profit Margin: +61% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

GiveHerTheDD Nov. 14 at 3:44 PM

$NSPR we've hit 50% held by institutions! 20% held by insiders! Even more shares held by employees with vestment schedules 3 years out. But we still have losers on this board saying that is it going to r/s 😂 last i checked, institutions don't invest money in anticipation of the stock price going down, right?

1 · Reply

HOBOWITHASHOTGUN Nov. 14 at 2:52 PM

$NSPR Buying more

2 · Reply

HedgeAlerts Nov. 14 at 7:49 AM

Hedge Alert Live - Protect Your Portfolio Contract: $NSPR $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.80 - $3.20 Exit Price Target: $1.50 Profit Margin: +88% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Threeways Nov. 14 at 3:07 AM

$NSPR Paul just keeps buying up shares. That man must really believe

0 · Reply

GiveHerTheDD Nov. 14 at 12:45 AM

$NSPR CREST-2 data being shared next week at VEITH and nspr has a huge lineup of professionals presenting on CGuard data

1 · Reply

JohnDoePower Nov. 13 at 9:16 PM

$NSPR 10K shares made me $1,500 today. Funneled the profits into $BLNE which is oversold, has hit a pretty solid support level, and has a VERY bright future (especially compared to some of its biggest competitors).

0 · Reply

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 10 days ago

InspireMD Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:30 AM EST - 11 days ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 24 days ago

InspireMD to Announce Third Quarter 2025 Financial Results

Oct 8, 2025, 8:00 AM EDT - 5 weeks ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 17, 2025, 8:00 AM EDT - 2 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Aug 27, 2025, 9:00 AM EDT - 2 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 12:30 PM EDT - 3 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 3 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 3 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 3 months ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 4 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 4 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 5 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 5 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 5 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 6 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 6 months ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 7 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 7 months ago

InspireMD to Announce First Quarter 2025 Financial Results

Mar 26, 2025, 9:00 AM EDT - 8 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 8 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 8 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 9 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 9 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 1 year ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 1 year ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 3, 2024, 7:00 AM EST - 2 years ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Dec 20, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Nov 27, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Nov 6, 2023, 11:09 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

DocRosen Nov. 15 at 3:30 AM

$NSPR ok quit with the rally. I’m trying to buy more.

0 · Reply

LiquidThetaOptions Nov. 15 at 1:04 AM

0 · Reply

Threeways Nov. 14 at 9:14 PM

$NSPR wheres all the complainers at 3 days of gaining off what it lost and its silence. Cant even say anything positive ever

1 · Reply

HedgeAlerts Nov. 14 at 6:30 PM

0 · Reply

GiveHerTheDD Nov. 14 at 3:44 PM

1 · Reply

HOBOWITHASHOTGUN Nov. 14 at 2:52 PM

$NSPR Buying more

2 · Reply

HedgeAlerts Nov. 14 at 7:49 AM

0 · Reply

Threeways Nov. 14 at 3:07 AM

$NSPR Paul just keeps buying up shares. That man must really believe

0 · Reply

GiveHerTheDD Nov. 14 at 12:45 AM

$NSPR CREST-2 data being shared next week at VEITH and nspr has a huge lineup of professionals presenting on CGuard data

1 · Reply

JohnDoePower Nov. 13 at 9:16 PM

0 · Reply

Threeways Nov. 13 at 7:13 PM

$NSPR JBinLB has to be the biggest idiot. Constantly complains the stock wont go up while simultaneously bashes the stock under every single post. Make it make sense. Way to help entice anyone from purchasing shares to help your position smart one…..

2 · Reply

DrewSerick Nov. 13 at 6:34 PM

$NSPR News ?

1 · Reply

JohnDoePower Nov. 13 at 3:49 PM

$NSPR Good morning. I'm curious how you're all feeling about the potential for (at least partial) recovery from all the panic selling that happened after their earnings report.

1 · Reply

woodstockery Nov. 12 at 6:51 PM

$NSPR drinking at $1.50 or $2.50 Right now NSPR is doing wonders for my liver.

1 · Reply

JBinLB Nov. 12 at 3:55 PM

$NSPR complete and udder joke. Dont touch it w a 10 ft pole. Unless you want your shares split every few years

0 · Reply

Ronnie5isAlive Nov. 12 at 2:47 AM

$NSPR

0 · Reply

Thespectator Nov. 11 at 9:34 PM

$NSPR toxic financing is not a theory, yet people still doubt cold hard facts as always

0 · Reply

Mt64 Nov. 11 at 8:48 PM

$NSPR unreal. I wonder what all of these institutional funds that have been buying this up over past 6 months are thinking at this point. Just sad.

1 · Reply

HOBOWITHASHOTGUN Nov. 11 at 8:28 PM

$NSPR Lions & Tigers & Bears - OH MY!

0 · Reply

Iightning Nov. 11 at 7:21 PM

1ightning® Options Trade Alert (Actionable) | Buy $NSPR Nov 21 $2 Call | Enter: $0.08 Exit: $0.13 | Profit: 70.72% ROI | https://1ightning.com

0 · Reply

JBinLB Nov. 11 at 7:11 PM

$NSPR 🐈‍⬛ 💩

0 · Reply

Ronnie5isAlive Nov. 11 at 5:56 PM

$NSPR can’t catch a break on this stock

0 · Reply

Market Cap	79.23M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	88,800
Avg Vol	127,842
Day's Range	N/A - N/A
Shares Out	42.37M
Stochastic %K	64%
Beta	0.64
Analysts	Strong Sell
Price Target	$4.50